Yupelri - (175 mcg/3 mL; Inhalation Solution)

Generic Name	Revefenacin	**Innovator**	Viatris - Theravance
Dosage	175 mcg/3 mL; Inhalation Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	More Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	None	**Generic Launches**	None
Indication	YUPELRI (revefenacin) inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.